# KURA catalysts: Kura Oncology, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/kura/catalysts

> Kura Oncology, Inc. (KURA) has 4 upcoming catalysts. The next is the darlifarnib trial start, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for KURA?

Kura Oncology, Inc. (KURA) has 4 upcoming catalysts. The next is the darlifarnib trial start, 1H 2027. Press release filed with the SEC (EX-99): "Initiate the planned single-arm monotherapy registrational study of darlifarnib in approximately 40 HRAS-mutant SGC patients in 1H 2027." [Calendar and source filings](https://sec-api.dev/companies/kura/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-455416, https://www.sec.gov/Archives/edgar/data/1422143/000119312526455416/kura-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/companies/kura/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Kura Oncology, Inc. |
| Ticker | KURA (Nasdaq) |
| SEC CIK | 1422143 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/kura |

## Cash runway

Cash $492.1M as of 2026-09-30; quarterly burn $54.4M; about 27.1 months of runway at that rate (XBRL company facts, accession 0001193125-26-455455).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2023 | [FIT-001 trial start](https://sec-api.dev/pdufa/fit-001) | KURA |  | completed | "In October 2023, we announced that we dosed the first patient in the monotherapy portion of the FIT-001 trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1422143/000095017025029975/kura-20241231.htm)) |
| February 26, 2024 | [KOMET-008 trial start](https://sec-api.dev/pdufa/komet-008) | KURA |  | completed | "On February 26, 2024, we announced that we dosed the first patient in KOMET-008." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1422143/000095017025029975/kura-20241231.htm)) |
| 1H 2025 | [KOMZIFTI (ziftomenib) trial start](https://sec-api.dev/pdufa/ziftomenib) | KURA | advanced GIST | scheduled | "We expect to initiate a Phase 1 trial evaluating ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure, which we refer to as the KOMET-015 trial, in the first half of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1422143/000095017025029975/kura-20241231.htm)) |
| February 5, 2025 | [KOMET-001 topline data readout](https://sec-api.dev/pdufa/komet-001) | KURA |  | completed, positive | "On February 5, 2025, we and Kyowa Kirin announced positive topline results from the Phase 2 portion of the KOMET-001 trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1422143/000095017025061848/kura-20250331.htm)) |
| February 26, 2025 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025027706/kura-ex99_1.htm)) |
| March 31, 2025 | [KOMZIFTI (ziftomenib) NDA/BLA submission](https://sec-api.dev/pdufa/ziftomenib) | KURA |  | completed | "On March 31, 2025, we submitted to the FDA a new drug application, or NDA, for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263589/kura-20250930.htm)) |
| Q2 2025 | [KOMZIFTI (ziftomenib) NDA/BLA submission](https://sec-api.dev/pdufa/ziftomenib) | KURA | with R/R NPM1-mutant AML | scheduled | "Facilitated by the Breakthrough Therapy Designation status of ziftomenib in R/R NPM1-m AML, the Company completed its pre-NDA meeting with FDA and anticipates submitting an NDA in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025027706/kura-ex99_1.htm)) |
| Q2 2025 | [KOMET-001 NDA/BLA submission](https://sec-api.dev/pdufa/komet-001) | KURA | relapsed or refractory NPM1-mutant AML | scheduled | "Based upon the results of the KOMET-001 trial and our pre-NDA meeting with the FDA, we expect to submit a new drug application, or NDA, to the FDA for ziftomenib for the treatment of relapsed or refractory NPM1-mutant AML in the second quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1422143/000095017025029975/kura-20241231.htm)) |
| April 28, 2025 | [KOMZIFTI (ziftomenib) trial start](https://sec-api.dev/pdufa/ziftomenib) | KURA | advanced GIST | completed | "On April 28, 2025, we announced that we dosed the first patients in a Phase 1 trial evaluating ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure, which we refer to as the KOMET-015 trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263589/kura-20250930.htm)) |
| May 1, 2025 | [KOMET-015 trial start](https://sec-api.dev/pdufa/komet-015) | KURA | advanced gastrointestinal stromal tumors | completed | "First patients dosed in KOMET-015 trial in GIST - Earlier this week, Kura announced the first patients have been dosed in its KOMET-015 Phase 1 clinical trial of ziftomenib in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025061836/kura-ex99_1.htm)) |
| May 1, 2025 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025061836/kura-ex99_1.htm)) |
| Jun 2025 | [KOMZIFTI (ziftomenib) PDUFA date](https://sec-api.dev/pdufa/ziftomenib) | KURA | relapsed or refractory | scheduled | "FDA Priority Review of New Drug Application for ziftomenib with PDUFA target action date of November 30, 2025 - In June 2025, Kura and Kyowa Kirin Co., Ltd. (Kyowa Kirin) announced the U.S. Food and Drug Administration (FDA) accepted Kura's NDA seeking full approval for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (NPM1-m)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025105024/kura-ex99_1.htm)) |
| June 1, 2025 | [KOMZIFTI (ziftomenib) NDA/BLA acceptance](https://sec-api.dev/pdufa/ziftomenib) | KURA | relapsed or refractory | completed | "On June 1, 2025, Kura Oncology, Inc. (the "Company") and Kyowa Kirin Co., Ltd. ("Kyowa Kirin") announced that the U.S. Food and Drug Administration ("FDA") has accepted the Company's New Drug Application ("NDA") seeking full approval for ziftomenib as a treatment for adult patients with relapsed or refractory ("R/R") acute myeloid leukemia ("AML") with a nucleophosmin 1 ("NPM1") mutation." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1422143/000119312525133717/d917067d8k.htm)) |
| June 1, 2025 | [KOMET-001 NDA/BLA acceptance](https://sec-api.dev/pdufa/komet-001) | KURA |  | completed | "On June 1, 2025, we and Kyowa Kirin announced that the FDA accepted our NDA, granted Priority Review of the NDA and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of November 30, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263589/kura-20250930.htm)) |
| 2H 2025 | [KOMET-017 trial start](https://sec-api.dev/pdufa/komet-017) | KURA |  | scheduled | "The companies also gained alignment with the EMA on the KOMET-017 protocol, and expect to initiate the KOMET-017 Phase 3 trials in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025027706/kura-ex99_1.htm)) |
| August 7, 2025 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025105024/kura-ex99_1.htm)) |
| August 7, 2025 | [KOMZIFTI (ziftomenib) NDA/BLA acceptance](https://sec-api.dev/pdufa/ziftomenib) | KURA |  | completed | "Enrollment in KOMET-001, a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-m AML, has been completed, and in the second quarter of 2025, the companies announced the FDA's acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-m AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025105024/kura-ex99_1.htm)) |
| September 29, 2025 | [KOMET-017 trial start](https://sec-api.dev/pdufa/komet-017) | KURA | newly diagnosed NPM1-mutated or KMT2A-rearranged AML | completed | "On September 29, 2025, we and Kyowa Kirin announced the first patient dosed under the KOMET-017 protocol, which is comprised of two independent, global, randomized, double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib in combination with both intensive and non-intensive regimens in patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263589/kura-20250930.htm)) |
| Oct 2025 | [KOMET-007 trial start](https://sec-api.dev/pdufa/komet-007) | KURA |  | completed | "In October 2025, we announced the first patient was dosed in the FLT3 inhibitor cohort of the KOMET-007 clinical trial (NCT05735184)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263491/kura-ex99_1.htm)) |
| Nov 2025 | [KOMZIFTI (ziftomenib) NDA/BLA submission](https://sec-api.dev/pdufa/ziftomenib) | KURA |  | completed | "Following the FDA's November 2025 approval of KOMZIFTI, we submitted patent information to our NDA regarding eight granted U.S. patents that claim the drug substance, drug product and/or methods of treatment for KOMZIFTI." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1422143/000119312526092567/kura-20251231.htm)) |
| November 4, 2025 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263491/kura-ex99_1.htm)) |
| November 13, 2025 | [KOMZIFTI (ziftomenib) FDA approval](https://sec-api.dev/pdufa/ziftomenib) | KURA | relapsed or refractory | completed, approved | "Komzifti \| ziftomenib \| 11/13/2025 \| To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| November 30, 2025 | [KOMZIFTI (ziftomenib) PDUFA date](https://sec-api.dev/pdufa/ziftomenib) | KURA | relapsed or refractory NPM1-m AML | completed, approved | "Continued regulatory interactions with the FDA ahead of the November 30, 2025 PDUFA target action date for ziftomenib as a monotherapy for adult patients with relapsed or refractory NPM1-m AML." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263491/kura-ex99_1.htm)) |
| November 30, 2025 | [KOMET-001 PDUFA date](https://sec-api.dev/pdufa/komet-001) | KURA |  | scheduled | "ZIFTOMENIB Targeted investigational menin inhibitor for relapsed/refractory and newly diagnosed acute myeloid leukemia (AML) New Drug Application (NDA) based on positive results from the Phase 2 KOMET-001 trial NDA granted Priority Review and assigned Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 Kyowa Kirin partnership funds expansive AML development program through 1L U.S. commercialization" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312525142816/d939526dex991.htm)) |
| March 5, 2026 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports Fourth Quarter and full year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312526092465/kura-ex99_1.htm)) |
| May 12, 2026 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports FIRST Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312526219422/kura-ex99_1.htm)) |
| August 12, 2026 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports SECOND Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312526346856/kura-ex99_1.htm)) |
| November 10, 2026 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312526455416/kura-ex99_1.htm)) |
| 1H 2027 | [Darlifarnib trial start](https://sec-api.dev/pdufa/darlifarnib) | KURA |  | scheduled | "Initiate the planned single-arm monotherapy registrational study of darlifarnib in approximately 40 HRAS-mutant SGC patients in 1H 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312526455416/kura-ex99_1.htm)) |
| 2028 | [KOMET-017 topline data readout](https://sec-api.dev/pdufa/komet-017) | KURA |  | scheduled | "- Topline MRD-negative CR results from KOMET-017-IC Phase 3 trial anticipated in 2028 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025027706/kura-ex99_1.htm)) |
| 2028 | [KOMET-017 interim data readout](https://sec-api.dev/pdufa/komet-017) | KURA |  | scheduled | "Initial topline results from the frontline KOMET-017 registrational program are anticipated in 2028, representing a key milestone in evaluating the potential to expand ziftomenib into newly diagnosed AML." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312526455416/kura-ex99_1.htm)) |
| 2028 | [KOMZIFTI (ziftomenib) topline data readout](https://sec-api.dev/pdufa/ziftomenib) | KURA |  | scheduled | "In addition, when combined with the anticipated $180.0 million in payments under the Kyowa License Agreement, we expect to have sufficient capital to advance our ziftomenib AML program through the first topline results from KOMET-017, anticipated in 2028." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1422143/000119312526346884/kura-20260630.htm)) |

## Drugs

- [Darlifarnib](https://sec-api.dev/pdufa/darlifarnib): 
- [FIT-001](https://sec-api.dev/pdufa/fit-001): 
- [KOMET-001](https://sec-api.dev/pdufa/komet-001): r/r npm1-mutant, relapsed or refractory npm1-mutant aml, relapsed/refractory
- [KOMET-007](https://sec-api.dev/pdufa/komet-007): 
- [KOMET-008](https://sec-api.dev/pdufa/komet-008): 
- [KOMET-015](https://sec-api.dev/pdufa/komet-015): advanced gastrointestinal stromal tumors
- [KOMET-017](https://sec-api.dev/pdufa/komet-017): newly diagnosed npm1-m or kmt2a-r aml, newly diagnosed npm1-mutated or kmt2a-rearranged aml
- [KOMZIFTI (ziftomenib)](https://sec-api.dev/pdufa/ziftomenib): relapsed or refractory, advanced gist, relapsed or refractory npm1-m aml, with relapsed or refractory acute myeloid leukemia, or aml, with relapsed or refractory aml, r/r npm1-m aml with prescription drug user fee act

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/kura/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KURA catalysts: Kura Oncology, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/kura/catalysts

```bibtex
@misc{secapidev_companies_kura_catalysts_20261116,
  title        = {KURA catalysts: Kura Oncology, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/kura/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_kura_catalysts_20261116","title":"KURA catalysts: Kura Oncology, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/kura/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
